drugset / Trial / NCT04940767

A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris

NCT04940767

Phase 4 Completed 31 enrolled Edward Lain, MD Vyne Therapeutics Inc. · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

Acne vulgaris is a common disease of both males and females, usually manifesting initially during adolescence. The use of retinoic acid analogues such as adapalene, tazarotene and isotretinoin are also commonly prescribed to treat inflammation; dysregulated sebum production and comedonal acne. This study seeks to evaluate the efficacy and safety of concomitant use of both AMZEEQ® and oral isotretinoin compared to oral isotretinoin only use and to explore sequence dosing of both products as part of a long-term management protocol for acne vulgaris.

Timeline

Start
2021-06-28
Primary completion
2023-04-28
Completion
2023-04-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Isotretinoin Other / unclassified Oral
Subject Minocycline Small molecule 4 % Topical

Indications